Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
Gene Editing Revamped with CRISPR Prime Editor – Result Is A High Efficiency, More Precise Gene Editor With Versatile Editing Capabilities And Lower Off-Target Effects
Nebion Provides Curated Omics Data Combined with Innovative Visualizations for Target Discovery, Indication Finding, and Drug Safety Assessment